As the Cannabis Growth Fund made its debut in the public market last Tuesday (February 26), the Investing News Network (INN) caught up with its portfolio manager Korey Bauer, a managing director with Foothill Capital Management.

For the fund, Bauer said it will focus on the long-term growth potential in a company, the branding abilities and the current market exposure.

The portfolio manager also highlighted taking a more critical look at the management team of a company, saying with the increasing costs these companies are incurring, it is “absolutely crucial” to study the leaders of a marijuana firm.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“In the next six-to-12 months, we’re going to start to see a breakaway between the leaders and the laggers,” Bauer said regarding Canadian firms.

In the Canadian cannabis market, 2019 will potentially mark the legalization and opening of the edibles and infused products space.

Recently, Bill Blair, Minister of the Cannabis Act, told Bloomberg the legalization in paper of edibles, doesn’t mean sales will start right away.

The Canadian government has until October 17, 2019 to legalize these products.

Bauer said the roll out of edibles will be “crucial” for the development of the market and to see the split between Canadian firms in control of the market, and those struggling to break through.

The Cannabis Growth Fund will not add any companies in the US dealing with the cannabis plant directly, according to Bauer, leaving the popular multi-state operators out of the investment picture.

“With some of these multi-state operators, no question they are taking up some quite a bit of market share pretty quickly,” he said. “I do think that’s going to make it a little bit more challenging for some of these Canadian companies to breach into the US.”

The initial holdings for the fund were not disclosed, but Bauer told INN the full list would be shared in a month or two.

According to the prospectus for the fund, Foothill Capital Management is expecting for “a large number” of the fund’s holdings to be Canadian companies.

Bauer said he expects to see pressure rise for Canadian companies focussed on pure producer plays in the market.

In terms of the upcoming cannabidiol (CBD) play in the US thanks to the legalization of hemp, Bauer told INN he expects the craze for this market to settle with sensible regulations from the US Food and Drug Administration in the near future.

The market for hemp-derived CBD has led to all type of players in the marijuana space to pursue specific ventures, including multi-state operators and Canadian leading licensed producers.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in contributed article. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Ayurcann Holdings Corp. (CSE: AYUR) (FSE:3ZQ0) (the “ Company ” or “ Ayurcann ”) a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has entered into a patient-referral agreement with The Herb Clinic (“ Clinic ”), providing Canadians guidance and access to managing discomfort with medicinal cannabis.

The Herb Clinic has over 4000 patients registered and is comprised of compassionate and knowledgeable service providers who are defined by their ability to provide exceptional patient care. They help educate and integrate cannabis into the patient’s medical treatment plans and partner with medicinal cannabis providers such as Ayurcann, to ensure their patients are getting top-quality advice with exceptional value.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today its “Summer of Social Justice” nationwide initiative raised over $250,000 for social justice-focused community organizations and supported the expungement process for over 1,000 individuals with cannabis-related criminal records.

This press release features multimedia. View the full release here:

Keep reading... Show less

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less